Noxafil (Posaconazole)

Posaconazole, the active ingredient in Noxafil, is an antifungal presented as a 300 mg tablet for oral use. It treats invasive fungal infections such as aspergillosis and candidiasis in immunocompromised patients. GNH USA supplies Noxafil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

GNH USA supplies Noxafil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Posaconazole is an antifungal agent used to manage serious fungal diseases, particularly in high‑risk patient groups.

- Invasive aspergillosis: helps control infection and improve survival in patients with compromised immunity. - Prophylaxis of fungal infections: prevents invasive candidiasis and aspergillosis in patients undergoing hematopoietic stem‑cell transplantation. - Refractory candidiasis: provides an oral treatment option when first‑line agents are ineffective. - Chronic pulmonary aspergillosis: reduces fungal burden and stabilises lung function. - Empirical therapy for febrile neutropenia: adds coverage against yeasts and molds when fever persists despite broad‑spectrum antibiotics.

Adverse reactions to posaconazole vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often transient. - Headache: mild, intermittent. - Elevated liver enzymes: mild increases in ALT/AST. - Fatigue: general tiredness. - Abdominal pain: cramping or discomfort.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury, jaundice or elevated bilirubin. - QT prolongation: cardiac rhythm disturbance that may predispose to arrhythmia. - Severe hypersensitivity: rash, angioedema, or anaphylaxis. - Visual disturbances: blurred vision or photophobia. - Thromboembolic events: rare clot formation. - Acute pancreatitis: sudden abdominal pain with elevated enzymes.

Posaconazole requires careful monitoring in several clinical situations.

- Liver function: assess baseline enzymes and monitor periodically. - Cardiac risk: evaluate QT interval in patients with known arrhythmias or electrolyte abnormalities. - Drug interactions: review concomitant medications that affect CYP3A4. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Renal impairment: adjust therapy based on clinical response, as no dose reduction is required. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Posaconazole interacts with several medicines through CYP3A4 inhibition and other pathways.

Major Interactions (Avoid): - Rifampicin: markedly reduces posaconazole exposure, compromising efficacy. - St. John’s wort: strong CYP3A4 inducer that lowers posaconazole levels. - Certain anti‑arrhythmics (e.g., amiodarone): may increase risk of QT prolongation.

Moderate Interactions (Monitor Closely): - Statins metabolised by CYP3A4 (e.g., simvastatin): may require dose adjustment. - Proton pump inhibitors: can reduce absorption of the oral suspension. - Midazolam: increased sedation due to CYP3A4 inhibition.